Smoot Hardly: the US-China trade war, prescription drug price legislation and the 2020 election - J.P. Morgan Asset Management
CLOSE

Smoot Hardly: the US-China trade war, prescription drug price legislation and the 2020 election

Contributor Michael Cembalest

Eye on the Market

I now believe that prospects for a deal are only 50/50 given China's withdrawal of concessions. The economic impact of a growing tariff conflict on the US is modest, but the hit to earnings could be worse. The negative market reaction is in part a consequence of how high valuations became after the spring 2019 rally. Also, how new research on US prescription drug prices vs other countries affects the prospects for drug price legislation. We conclude with an updated ideological scorecard for 2020 Presidential candidates and their policies.

Continue Reading  

Subscribe to the podcast to get the latest updates:

    Listen on Google Play Music  

Google Play may not be available in your country